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The development of sensitive and non-invasive
‘‘liquid biopsies’’ presents new opportunities for
longitudinal monitoring of tumor dissemination and
clonal evolution. The number of circulating tumor
cells (CTCs) is prognostic in multiple myeloma
(MM), but there is little information on their genetic
features. Here, we have analyzed the genomic land-
scape of CTCs from 29 MM patients, including eight
cases with matched/paired bone marrow (BM) tumor
cells. Our results show that 100% of clonal mutations
in patient BMwere detected in CTCs and that 99% of
clonal mutations in CTCs were present in BM MM.
These include typical driver mutations in MM such
as in KRAS, NRAS, or BRAF. These data suggest
that BM and CTC samples have similar clonal struc-
tures, as discordances between the two were
restricted to subclonal mutations. Accordingly, our
results pave the way for potentially less invasive
mutation screening of MM patients through charac-
terization of CTCs.
INTRODUCTION
The development of ‘‘liquid biopsies’’ presents new opportu-
nities for non-invasive monitoring of clonal heterogeneity (Law-
rence et al., 2014). Multiple myeloma (MM) is a plasma cell
(PC) malignancy characterized by patchy bone marrow (BM)
infiltration. Recent studies of massive parallel sequencing of
tumor cells obtained from the BM of patients with MM have
demonstrated significant clonal heterogeneity in MM with a me-
dian of five clones present in each sample (Lohr et al., 2014b;218 Cell Reports 19, 218–224, April 4, 2017 ª 2017 The Authors.
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clonal heterogeneity, it could be envisioned that such clonal di-
versity may be even higher since single BM samples only repre-
sent a small fraction of the whole BM compartment, and the
pattern of BM infiltration in MM is typically patchy. In addition,
BM biopsies are painful and cannot be repeated multiple times
during the course of therapy, indicating a need for less invasive
methods to molecularly characterize MM patients and monitor
disease progression during the therapy. Thus, optimal charac-
terization of circulating tumor cells (CTCs) may represent a
non-invasive method to capture relevant mutations present in
PC clones. However, it is presently unknown whether using
liquid biopsies (i.e., patients’ genetic characterization performed
in peripheral blood [PB] samples) can provide a more complete
profile of MM clonal diversity. Unlike other hematological malig-
nancies (e.g., leukemia), MM does not have a substantial
numbers of CTCs burden except in late stages of disease pro-
gression such as in PC leukemia. Of note, standard exome
sequencing has recently been performed in single CTCs in pros-
tate cancer, demonstrating that 70% of CTC mutations were
present in matched tumor tissue (Lohr et al., 2014a).
Here, we used sensitive multiparameter flow cytometry (MFC)
to detect and isolate CTCs in the PB of MM patients. We per-
formed whole-exome sequencing in sorted CTCs and compared
their mutational profile to that of patient-paired BM clonal PCs.
Confirmatory studies using a targeted sequencing panel demon-
strate fidelity of the mutational profile observed in those with
matched BM and CTC samples. Thus, our results reveal that
CTCs can potentially be used as a non-invasive biomarker to
perform mutational profiling of MM patients.
RESULTS
We first determined the mutational profile of CTCs of patients
with MM of eight matched CTC samples compared to pairedcreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Concordance of SSNVs Found in Matched BM Clonal PCs and CTCs
(A) Rate of synonymous and nonsynonymousmutations are expressed in number of mutations per megabase. Heatmap representation of individual mutations is
present in a series of eight paired BM and CTC samples. Breakdown of individual base-substitution rates is shown for each sample as well.
(B) Heatmap representation of individual mutations is present in 13 WES CTC samples and 16 targeted sequencing CTC samples. Percentages represent the
fraction of tumors harboring at least one mutation in specified genes.BM tumor cells and germline non-tumor cell DNA from PB T lym-
phocytes. We identified 658 and 572 coding somatic single-
nucleotide variants (SSNVs) in patient-paired BM clonal PCs
and CTCs, respectively. Overall, 90% of CTC mutations were
present in BM tumors and 93% of BM mutations were present
in CTC samples, and, upon analyzing the mutational variants
by nucleotide change, we found that the percentages of each
change in BM myeloma PCs and CTCs were concordant. We
then focused on the variants that are well known to be driver mu-
tations in myeloma and other cancers, to define/investigate the
role of CTCs in being a good surrogate for the most relevant var-
iants observed in BM samples. Among 70MM-related genes and246 pan-cancer driver genes (Weinstein et al., 2013; Omberg
et al., 2013), a total of 18 somatic single nucleotide variants
(SSNVs) in 13 genes were identified in our cohort, and ten out
of the 13 genes were matched between BM clonal PCs and
CTCs. It is noteworthy that the genes with the highest frequency
in MM, such as KRAS, NRAS, and BRAF, were present in these
samples and were shared between patient-paired BM clonal
PCs and CTCs (Figure 1A).
The frequency of mutated genes in MM patients and pan-can-
cer driver genes in CTCs was further investigated in a subse-
quent analysis of additional samples. Therefore, we analyzed
five CTC samples by whole-exome sequencing (withoutCell Reports 19, 218–224, April 4, 2017 219
Figure 2. Clustering Analysis of Clonal and Subclonal SSNVs between Matched BM Clonal PCs and CTCs
Clustering analysis of CCF for SSNVsbetweenmatchedBMclonal PCs andCTCs is shown in this figure. Shared clonal SSNVswere defined as events havingR0.9
CCF inboth samples (red). Shared subclonal SSNVswere identified asevents havingR0.05CCF inboth samples (blue).Not shared subclonal SSNVsweredefined
as events having <0.05 CCF in either BM or CTC samples (green). The size of each cluster indicates the frequency of SSNVs within the same sample.whole-exome amplification) and 16 CTC samples by deep-tar-
geted sequencing (9003) using a custom-developed panel.
These additional 21 patients (without available paired BM tumor
cells) showed similar mutational profiles (Figure 1B) as
compared to the first cohort with matched BM tumor cells and
CTCs, as well as previous reports on mutation analyses from
BM tumor cells (Bolli et al., 2014; Lohr et al., 2014b; Walker
et al., 2015). The higher frequency of mutations detected in the
later 16 patients was related to the deeper coverage of the tar-
geted sequencing approach.
After showing that CTCs were a representative tumor
compartment for mutation screening in MM, we then investi-
gated the clonal distribution between BM myeloma clonal PCs
and CTCs in order to compare clonal and subclonal architec-
tures between each tissue-specific clone (Figure 2). Overall,
100%of clonalmutations in BMwere confirmed in CTC samples,
and 99% of clonal mutations in CTCs were present in BM tu-
mors. On the other hand, 88% of subclonal mutations in BM
were confirmed in CTC samples, and 81% of subclonal muta-
tions in CTCs were confirmed in BM clonal PC samples. In other
words, we observed that 84% of these clonal and subclonal
SSNVs were shared between BM and CTC samples (i.e., cancer
cell fraction [CCF] >0.05 in both samples), 42% (range 22%–
73%) of SSNVs were clonal (i.e., cancer cell fraction, CCF
R0.9), and 42% (range 18%–65%) of SSNVs were found to be
subclonal (i.e., CCF <0.9). Conversely, 16% (range 0%–50%)
of SSNVs were subclonal and not shared between BM tumor
PCs and CTCs (i.e., CCF <0.05 in either BM clonal PCs or CTCs).
Since specific cytogenetic abnormalities are of major impor-
tance for risk stratification in MM, we further evaluated somatic
copy-number alterations (SCNAs) and compared them between
matched BM and PB tumor cells across paired samples (Figures220 Cell Reports 19, 218–224, April 4, 20173 and 4). A concordance between BM clonal PCs and CTCs was
observed in 92% (range 77%–100%) of arm level SCNAs.
Classic MM-related SCNAs, such as 1q21 amplification and
13q deletion, were present both on BM clonal PCs and CTCs
from some patients (Figure 3) (Corre et al., 2015; Walker et al.,
2010; Mohamed et al., 2007; Jenner et al., 2007). Two examples
of the concordance observed between BM and CTC SCNAs are
provided in Figure 4, in which we were able to detect, in individ-
ual patients, concordant patterns of SCNAs between BM and
CTC samples.
DISCUSSION
In MM, there is a marked fluctuation of different clones
throughout patients’ clinical course, implying that multiple BM
aspirates are needed to determine the genomic profile of pa-
tients, specifically with the development of new targeted thera-
pies for actionable mutations (e.g., BRAF inhibitors for patients
with BRAF mutations). Accordingly, the primary objective of
our study was to determine the feasibility of performing genomic
characterization of MM patients non-invasively and define
whether the mutation profile of CTCs reflected that of patient-
paired BM clonal PCs.
The field of liquid biopsies is one of the more intensively inves-
tigated areas of research in oncology at this time.We felt that this
should also be a priority in MM, a disease in which patients go
through a large number of BM aspirates to determine their
genomic profile before starting a new line of therapy. In the pre-
sent study, we demonstrated that whole-exome sequence of
MM CTCs is feasible by combining highly sensitive multicolor
flow cytometry that enabled us to detect and collect a sufficient
number of purified CTCs with optimized molecular approaches.
Figure 3. Concordance of Somatic Copy-Number Alterations Found
in Matched BM Clonal PCs and CTCs
Arm level of somatic copy-number alterations are compared within the same
patient (left, BM; right, CTC). Red indicates amplification, and blue indicates
deletion.Regarding the frequency of patients with sufficient CTCs for ge-
netic studies in PB, our recent experience using ultra-sensitive
next-generation flow cytometry is that CTCs are detectable in
61% of monoclonal gammopathy of undetermined significance
(MGUS) and 100% of smoldering and active MM (newly diag-
nosed and relapsed). The median number of CTCs per microliter
in the blood of patients with MGUS, smoldering MM, and active
MM are 0.011, 0.14, and 2.01, respectively (Sanoja et al., 2015).
Accordingly, in patients with active MM as much as 15–20 mL of
blood would suffice to sort 30,000 CTCs in a significant fraction
of patients. A recent publication by Lohr et al. describes a
method that allows for the isolation and genomic characteriza-
tion of single MM CTCs by targeted sequence (Lohr et al.,
2016). Meanwhile, whole-exome sequencing has great advan-
tages against targeted sequencing approach, which includes
detection of non-recurrent but potential driver gene mutations,
deconvolution of copy-number alteration, and analysis of clonal
structure of the patient’s tumor. Indeed, we demonstrated in this
study that similar mutation patterns and SCNA are typically
observed for clonal as well as subclonal mutations. However,
discordant genomic alterations between matched BM clonal
PCs and CTCs were also detected. Further studies in larger se-
ries are warranted to address whether SSNVs present in CTCs
but not in BM tumor cells from some patients are a proof of
concept that single BM biopsies afford limited information due
to patchy infiltration and extramedullary disease. Conversely,
the fact that in other patients BM clonal PCs show higher
numbers of SSNVs reopens the question of whether CTCs are
more immature and therefore display lower subclonal mutations,
or whether we are witnessing unknown levels of spatial hetero-
geneity in which tumor cells from the same patient but isolated
from different tissues will consistently show differences in sub-clonal mutations (Gerlinger et al., 2012). Alternatively, differ-
ences in total number of mutations observed between BM
and CTC samples may also be attributable to differences in
detection sensitivity for subclonal mutations. Most of the
discrepant variants were subclonal mutations, and all clonal mu-
tations were shared between BM and CTC samples. Even
though intertumoral heterogeneity has been already described
when sequencing two tumor biopsies from the same patient
(Gerlinger et al., 2012), we believe that the discrepancy could
also be driven by the effect of whole-genome amplification in
some of the samples.We attempted to be strict in calling variants
in the samples that underwent whole-genome amplification
because we took only the shared variants identified in two paral-
lel libraries constructed by two different WGA reactions to elim-
inate random errors caused by whole-genome amplification,
and, by doing that, we had a smaller number of variants called
in the CTC samples. Indeed, these results are similar to studies
that have shown that the false-positive rate of WGA can be over-
come by taking the consensus of two independent WGA reac-
tions (Lohr et al., 2014a; Zhang et al., 2015).
With the development of better technologies and sequencing of
longitudinal CTCs, we may be able to use PB samples to deter-
mine the mutational landscape of MM patients during disease
presentation and progression. This approach could eliminate
the need for multiple invasive BM aspirates to determine genomic
alterations and monitor clonal evolution during disease progres-
sion and after therapeutic interventions. Additional efforts are
warranted to define, in large series of patients, the level of concor-
dance for SCNA and translocations between (whole genome/
exome or targeted) sequencing versus the gold standard fluores-
cence in situ hybridization (FISH). An additional question to be ad-
dressed is the potential association between the mutation profile
of CTCs and clinical outcomes; however, it should be noted that
the prognostic significance of mutation profiling in MM remains
largely unknown, and, perhaps, its major application could be to
personalize patients’ treatment rather than prognostication.
Together, this study defines a new role for CTCs in the prognostic
and molecular profiling of MM patients.EXPERIMENTAL PROCEDURES
Patient Sample Collection and Study Approval
We prospectively collected samples from patients seen in the clinic at Dana-
Farber Cancer Institute (DFCI) or Clinica Universidad de Navarra from 2011
to 2015. Among 29 unique patients with MM, we obtained eight samples of
newly diagnosed untreated patients whose bone marrow, CTC, and germline
T lymphocytes were available and selected for paired exome sequencing.
Additional whole-exome sequencing studies were performed in five patients
with flow-sorted CTCs but without available BM clonal PCs.
The review boards of participating centers approved the study, which was
conducted according to the Declaration of Helsinki and International Confer-
ence on Harmonization Guidelines for Good Clinical Practice. All patients pro-
vided written informed consent. The study approval numbers are 07-150
(DFCI) and 073/2015 (Clinica Universidad de Navarra).
Whole-Exome Sequencing
BM myeloma PCs and CTCs were sorted from paired BM and PB from eight
patients with symptomatic MM using a fluorescence-activated cell sorting
FACSAria IIb sorter (BD Biosciences). Both tumor fractions were sorted ac-
cording to the individual patient-specific aberrant phenotypes, and PBCell Reports 19, 218–224, April 4, 2017 221
Figure 4. Representative Example of Somatic Copy-Number Alterations Found in Matched BM Clonal PCs and CTCs
Allelic copy number ratios are shown for both BM (top) and CTC (bottom) samples within the same patient (434 and 453, respectively).
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T lymphocytes were simultaneously collected for germline control. Genomic
DNA was extracted using QIAamp DNA micro kit (QIAGEN) according to the
manufacturer’s protocols, and double-stranded DNA concentration was
quantified using PicoGreen dsDNA Assay kit (Life Technologies). The cell
number of CTCs used and total amount of genomic DNA obtained are shown
in Table S1.
For cases in which the total amount of DNA extracted from BM myeloma
PCs (n = 1) and CTCs (n = 7) was limited, the genomic DNA was amplified
using GenomePlex Whole Genome Amplification (WGA) Kits (Sigma-Aldrich)
according to the manufacturer’s instructions. To capture the coding regions,
we used the SureSelectQXT Target Enrichment kit (Agilent). All sequencing
was performed on the Illumina HiSeq 2000 platform (Illumina) at the New
York Genome Center or at the Broad Institute.
A detailed description of data processing is provided in the Supplemental
Experimental Procedures.Quality Control of Sequencing Data
For details, see Supplemental Experimental Procedures.Curation of MM and Pan-Cancer Driver Genes
For details, see Supplemental Experimental Procedures.Targeted Sequencing of CTCs
CTCs were magnetically enriched with anti-human CD138 antibody conju-
gated with microbeads (Miltenyi Biotec) from 10 mL of PB of patients with
symptomatic MM.
A detailed description of the procedure is provided in the Supplemental
Experimental Procedures.Statistical and Bioinformatics Analysis
Characterizing the Shared and Unique SNVs in BM Clonal Cells and
CTCs
Single-nucleotide variants (SNVs) were called by MuTect (Cibulskis et al.,
2013) by comparing tumor samples to matched normal samples using default
parameters, with an additional filter that requires at least three high-quality
reads supporting alternative variants.Estimation of SSNV Cancer Cell Fraction and Clonal Dynamic
The algorithm ABSOLUTE was applied to estimate sample purity, ploidy, and
absolute somatic copy numbers (Carter et al., 2012; Landau et al., 2013).
These were used to calculate and compare the cancer cell fraction of SSNVs
that were identified from MuTect and manually reviewed calling in both BM
clonal PCs and CTCs via PHYLOGIC (Brastianos et al., 2015; Stachler et al.,
2015). Clonal SSNVs were defined with a CCF >0.9. Shared subclonal SSNVs
were defined with a CCF >0.05 in both BM and CTC samples. We defined non-
shared subclonal SSNVs in either BM or CTC samples as those with a CCF
lower than 0.05.Somatic Copy-Number Alteration Identification
To estimate somatic copy-number alteration, we used ReCapSeg (http://
gatkforums.broadinstitute.org/gatk/categories/recapseg-documentation),
which calculated proportional coverage for each target region and then
normalized each segment using the median proportional coverage in a panel
of normal (PON) samples sequenced with the same capture technology. The
sample was projected to a hyperplane defined by the PON, and the tumor
copy ratio was estimated. These copy-ratio profiles were segmented with cir-
cular binary segmentation (CBS) (Venkatraman andOlshen, 2007). To estimate
allelic copy number, germline heterozygous sites in the normal sample were
called via GATK Haplotype Caller. Then, the contribution of each homologous
chromosome was assessed via reference and alternate read counts at the
germline heterozygous sites. Finally, we segmented the allele specific copy ra-
tios using R package PSCBS. After accounting for purity and ploidy of each
sample, we identified significant somatic copy-number alterations across
the samples via GISTIC 2.0 (Mermel et al., 2011).ACCESSION NUMBERS
The accession number for the BAM files reported in this paper is NCBI dbGaP:
phs001323.
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